Main Article Content

Aruna Rani Behera
Sangeeta Panigrahy
Pulavarthi Samatha
Basava Siva Prasad Reddy


COVID‐19, Prognostic marker, Inflammatory response, Disease severity, Disease progression, Serum marker


Background: Since its emergence in China in December 2019, SARS-CoV-2 has posed significant global health challenges due to its rapid spread and high mortality. Predicting COVID-19 severity remains difficult, with some suggesting C-reactive protein (CRP) as a potential early marker for severe cases. This study examines the relationship between CRP levels and COVID-19 severity to better manage the disease and aimed to investigate CRP’s utility in prognosticating COVID-19 to improve patient outcomes The study has included patients of more than 18 years diagnosed with COVID-19 infection by RT-PCR method and admitted in either ward or ICU or having any comorbid conditions eg: Diabetes, Hypertension.

Materials and Methods: Analysis regarding serum CRP with the severity of disease was done. Among all statistical tests, Chi-square tests were used where P <0.05 was taken as significant. This two-month retrospective study at Great Eastern Medical School and Hospital, Andhra Pradesh, analyzed data from 152 COVID-19 patients confirmed by RT-PCR. Data on demographics, clinical histories, and CRP levels determined by nephelometry were extracted from the hospital’s Laboratory Information System, following ethical approval.

Results: Analysis of 152 COVID-19 patients showed those with CRP levels >100 mg/L had a higher likelihood of severe disease. The values were categorised based on the values we received after the investigation. And the patients were suffering from more severe conditions who had >100mg/L of CRP values. The severity was determined based on the symptoms and signs patients presented during their stay in hospital. The majority (76.3%) had non-severe cases, with a significant 23.7% presenting with severe symptoms. CRP values ranged, with most patients having levels between 8.01-50.0mg/L or <8mg/L, correlating to illness severity.

Conclusion: High CRP levels may serve as an early indicator of potential disease severity in COVID-19, aiding timely intervention. While limited by sample size and being a single-center retrospective analysis, these findings call for larger, multicenter studies with repeated CRP measures for validation. Monitoring high-CRP patients closely is recommended.

Abstract 72 | PDF Downloads 37


1. Callaway E, Cyranoski D, Mallapaty S, Stoye E, Tollefson J. Coronavirus by the numbers. Nature. 2020; 579 (7800): 482-3.
2. Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population-based cohort study. BMJ. 2018 24;363.
3. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Annals of clinical microbiology and antimicrobials. 2020 :19(1):1-7.
4. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y et al. C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. Journal of medical virology. 2020;92(7):856-62.
5. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al Predictors of mortality in hospitalized COVID‐19 patients: a systematic review and meta‐analysis. Journal of medical virology. 2020 ;92(10):1875-83.
6. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al . C-reactive protein level may predict the risk of COVID-19 aggravation. InOpen forum infectious diseases 2020 (Vol. 7, No. 5, p. ofaa153). US: Oxford University Press.
7. Ali N. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients? Clinics and Research in Hepatology and Gastroenterology. 2020;44(4): e84.
8. Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. Journal of medical virology. 2020 ;92(10):1733.
9. Qu G, Huang G, Zhang M, Yu H, Song X, Zhu H, et al . Features of C-reactive protein in COVID-19 patients with different ages, clinical types, and outcomes: a cohort study. medRxiv. 2020 31:2020-10.
10. Bwire GM. Coronavirus: why men are more vulnerable to Covid-19 than women? SN comprehensive clinical medicine. 2020 ;2(7):874-6.
11. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. American journal of respiratory and critical care medicine. 2020 1;202(5):756-9.
12. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clinical immunology. 2005 1;117(2):104-11.
13. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991 1;23(2):118-24.
14. Ballou SP, Kushner I. C-reactive protein, and the acute phase response. Advances in internal medicine. 1992; 37:313-36.
15. Mo P, Xing Y, Xiao YU, Deng L, Zhao Q, Wang H, et al Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin infect dis. 2020 16:10.
16. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al . Prognostic value of C-reactive protein in patients with coronavirus 2019. Clinical Infectious Diseases. 2020 15;71(16):2174-9.
17. Tadic M, Cuspidi C. The influence of diabetes and hypertension on outcome in COVID‐19 patients: Do we mix apples and oranges? The Journal of Clinical Hypertension. 2021 ;23(2):235.
18. Azar WS, Njeim R, Fares AH, Azar NS, Azar ST, El Sayed M, et al . COVID-19 and diabetes mellitus: how one pandemic worsens the other. Reviews in Endocrine and Metabolic Disorders. 2020; 21:451-63.

Most read articles by the same author(s)